Feldan receives investment from Linearis

On February 18th 2025, Feldan Therapeutics announced an investment from Linearis ventures. This investment is geared towards supporting the progression of Feldan's lead candidate, FLD-103, a non-surgical treatment for basal cell carcinoma (BCC) currently in clinical trials as well as advance the expansion of its pipeline of transformative compounds.

Feldan Therapeutics, located in Québec City, Québec, is a clinical-stage pharmaceutical company focusing on the development of treatments through the intracellular delivery of therapeutics.

Linearis Ventures, based in Montreal, Canada is a venture capital firm specializing in supporting the artificial intelligence, healthcare, and metabolomics sectors through direct investments.

McCarthy Tétrault LLP advised Feldan Therapeutics with a team led by Charles-Antoine Soulière that included, Alexandre Saulnier-Marceau, Mireille Trottier, Kim Godbout and Yassine Khadir (Business).